BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu J, Zhu Z, Yu Q, Ding C. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials. Expert Opin Investig Drugs 2019;28:1113-23. [PMID: 31738612 DOI: 10.1080/13543784.2019.1692812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Byun JY, Koh YT, Jang SY, Witcher JW, Chan JR, Pustilnik A, Daniels MJ, Kim YH, Suh KH, Linnik MD, Lee YM. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection. Sci Rep 2021;11:18671. [PMID: 34548595 DOI: 10.1038/s41598-021-98255-7] [Reference Citation Analysis]
2 Liu Q, Hua L, Bao C, Kong L, Hu J, Liu C, Li Z, Xu S, Liu X. Inhibition of Spleen Tyrosine Kinase Restores Glucocorticoid Sensitivity to Improve Steroid-Resistant Asthma. Front Pharmacol 2022;13:885053. [DOI: 10.3389/fphar.2022.885053] [Reference Citation Analysis]